- A Phase 3 study on the efficacy and safety of Epirus' BOW015 rheumatoid arthritis drug relative to the currently-available Remicade "met its pre-specified statistical endpoint," and found "no meaningful differences observed in safety or immunogenicity."
- Results from the open label testing phase, including "one year immunogenicity, one year safety, and long-term responder rates," are expected in Q3.
- Epirus merger partner Zalicus (ZLCS) is responding quite well to the news.
Zalicus +43.5% AH; Epirus releases positive BOW015 data
From other sites
Presentations and Quarterly Reports - Research Report on NPS, Zalicus, Charles River, Insulet, and Sagentat CNBC.com (Nov 14, 2013)
at CNBC.com (Nov 11, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs